Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial
<p><strong>Background:</strong> The effects of the sodium-glucose co-transporter-2 inhibitor empagliflozin on renal and cardiovascular disease have not been tested in a dedicated population of people with chronic kidney disease (CKD).</p> <p><strong>Methods:</...
| Auteurs principaux: | , , |
|---|---|
| Autres auteurs: | |
| Format: | Journal article |
| Langue: | English |
| Publié: |
Oxford University Press
2022
|